Form 4 Filing for Agios Pharmaceuticals, Inc.

Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, Inc., reported transactions on July 1, 2026. Gheuens acquired 8,375 shares of common stock through the settlement of restricted stock units with a transaction value of $0. This was followed by the disposal of 4,007 shares of common stock at a price of $37.56 per share to cover tax withholding obligations related to the vesting of her restricted stock units. These transactions were executed under automatic sale instructions consistent with Rule 10b5-1(c) of the Securities Exchange Act. Following these transactions, Gheuens holds 84,645 shares of common stock directly.